Evidence map›Paper›PMID 26119008›Full record

ArticleJournal of veterinary internal medicine

Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.

J H Burton, R O Venable, D M Vail, L E Williams, C A Clifford, S M Axiak-Bechtel, A C Avery, D H Thamm

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

J H BurtonFlint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO.
R O VenableFlint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO.
D M VailSchool of Veterinary Medicine and the Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI.
L E WilliamsDepartment of Clinical Sciences, North Carolina State University, Raleigh, NC.
C A CliffordRed Bank Veterinary Hospital, Tinton Falls, NJ.
S M Axiak-BechtelDepartment of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO.
A C AveryFlint Animal Cancer Center, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO.
D H ThammFlint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO.
Colorado State University · USArizona Oncology · USMissouri College · USNorth Carolina State University · USTD Bank · USUniversity of California, Davis · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNonresectable mast cell tumors (MCT) in dogs remain a therapeutic challenge, and investigation of novel combination therapies is warranted. Intermittent administration of tyrosine kinase inhibitors (TKI) combined with cytotoxic chemotherapy may effectively chemosensitize canine MCT while decreasing cost and adverse effects associated with either agent administered as monotherapy. HYPOTHESIS/

objectivesThe primary study objectives were to (1) identify the maximally tolerated dose (MTD), (2) determine the objective response rate (ORR) and (3) describe the adverse event profile of pulse-administered toceranib phosphate (TOC) combined with lomustine. ANIMALS: Forty-seven client-owned dogs with measurable MCT.

methodsToceranib phosphate was given PO on days 1, 3 and 5 of a 21-day cycle at a target dosage of 2.75 mg/kg. Lomustine was given PO on day 3 of each cycle at a starting dosage of 50 mg/m(2) . All dogs were concurrently treated with diphenhydramine, omeprazole, and prednisone.

resultsThe MTD of lomustine was established at 50 mg/m(2) when combined with pulse-administered TOC; the dose-limiting toxicity was neutropenia. Forty-one dogs treated at the MTD were evaluable for outcome assessment. The ORR was 46% (4 complete response, 15 partial response) and the overall median progression-free survival (PFS) was 53 days (1 to >752 days). On multivariate analysis, variables significantly associated with improved PFS included response to treatment, absence of metastasis, and no previous chemotherapy. CONCLUSIONS AND CLINICAL IMPORTANCE: Combined treatment with pulse-administered TOC and lomustine generally is well tolerated and may be a reasonable treatment option for dogs with unresectable or metastatic MCT.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingDog DiseasesDogsDrug Administration ScheduleDrug Therapy, CombinationFemaleIndolesLomustineMaleMastocytosisPolymerase Chain ReactionProtein-Tyrosine KinasesProto-Oncogene Proteins c-kitPyrrolesAntineoplastic Agents, AlkylatingIndolesLomustineProtein-Tyrosine KinasesProto-Oncogene Proteins c-kitPyrrolestoceranib phosphateCancerChemotherapyDogTyrosine kinase inhibitor

Identifiers

PMID26119008
PMCPMC4895362
OpenAlexW1578355229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.